NBIX Is Knocking on Its 52-Week High, and the Fundamentals Justify a Breakout

Signal: BUY | Score: 67.41/100

Neurocrine Biosciences is sitting at $169.17, less than 2% below its 52-week high of $171.43, and this is not a stock running on hype. It just posted a blowout quarter, launched a second blockbuster drug, and trades at a forward P/E of just 13.4x. The market is sleeping on this one.

The Setup

NBIX is in a clean uptrend, up roughly 38% from its 52-week low of $122.14. The RSI sits at 64.8, which is strong without being overbought territory. Momentum score clocks in at 71.25, one of the strongest reads across the composite, and the stock is coiling right under resistance at the 52-week high. A clean break above $171.43 with any volume confirmation and this thing has open air above it. The technical score of 60.34 is solid rather than spectacular, which tells you this is not a crowded momentum trade. It is a fundamental story with technical confirmation.

The Catalyst

This is where it gets interesting. On May 5, NBIX reported Q1 2026 EPS of $1.94 against a $1.61 consensus, a 20% beat. Revenue came in at $814.5 million, up 42% year over year. INGREZZA continues to be a cash machine, and the CRENESSITY launch is adding a second engine to the business. Then, in early June, the company presented two-year CRENESSITY durability data at ENDO 2026, which matters because payers want long-term outcomes data before opening the floodgates on reimbursement. That data puts a floor under the CRENESSITY ramp story. Management also reaffirmed 2026 INGREZZA guidance of $2.7 billion to $2.8 billion, which removes a major uncertainty ahead of the next earnings report on July 29.

Bull Case

The forward P/E of 13.4x on a company growing earnings 24% year over year gives you a PEG ratio of just 0.48. That is genuinely cheap for this kind of growth profile.
Analyst consensus target is $195.06, implying roughly 15% upside from current levels with a "strong buy" recommendation.
CRENESSITY is still early innings. Two-year data strengthens the reimbursement story and the next 12 months should show meaningful revenue contribution.

Bear Case

Debt-to-equity of 13.6 is elevated and worth watching, especially if rates stay higher for longer.
A director sold 25,000 shares on June 5. Not a red flag on its own, but worth noting heading into the next earnings print.

The Trade

Entry: $169.17
Target: $195.00
Stop Loss: $158.00
Risk/Reward: Approximately 2.4:1
Timeframe: 8 to 12 weeks, with Q2 earnings on July 29 as the next key event

*This is one person's analysis, not financial advice. Always do your own research.*